Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

This is an open label Phase II Trial that using the investigational anti-cancer agent, Pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by decreasing the size of the tumor or stopping its growth.

Key facts

Study ID

NCT01262820

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

15

Starts

2010-12-01

Expected to finish

2014-10-01

Last updated by the study team

2017-03-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Stage IIIB (with malignant pleural or pericardial effusion or supraclavicular lymph node involvement) or stage IV NSCLC
• Evidence of progression while on bevacizumab
• Patients treated for CNS metastases who are asymptomatic with no requirement for steroids for 2 weeks prior to first dose of study drug

You may not qualify if…

• Prior malignancy
• Clinically significant gastrointestinal abnormalities
• Presence of uncontrolled infection or nonhealing wound, fracture, or ulcer
• History of cardiovascular conditions within the past 6 months

Where it is running

• North Carolina Cancer Hospital at U of North Carolina at CH — Chapel Hill, North Carolina, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.